Next Article in Journal
Molecular Basis of Mismatch Repair Protein Deficiency in Tumors from Lynch Suspected Cases with Negative Germline Test Results
Next Article in Special Issue
Insights into the Role of microRNAs in Colorectal Cancer (CRC) Metabolism
Previous Article in Journal
Desmoid-Type Fibromatosis
Previous Article in Special Issue
The Possible Influence of Mediterranean Diet on Extracellular Vesicle miRNA Expression in Breast Cancer Survivors
Review

A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies

1
UMR DIATHEC, EA 7294, Centre Européen d’Etude du Diabète, 67200 Strasbourg, France
2
Department of Cardiovascular Physiology, Tokyo Medical and Dental University, Tokyo 113-8510, Japan
3
Lyman Briggs College, Michigan State University, East Lansing, MI 48825, USA
4
Institute for Quantitative Health Sciences and Engineering (IQ), Michigan State University, East Lansing, MI 48824, USA
5
Department of Biomedical Engineering, Michigan State University, East Lansing, MI 48824, USA
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(7), 1852; https://doi.org/10.3390/cancers12071852
Received: 22 June 2020 / Revised: 6 July 2020 / Accepted: 7 July 2020 / Published: 9 July 2020
(This article belongs to the Special Issue MicroRNA Therapeutics: Towards a New Era for the Management of Cancer)
In the field of molecular oncology, microRNAs (miRNAs) and their role in regulating physiological processes and cancer pathogenesis have been a revolutionary discovery over the last decade. It is now considered that miRNA dysregulation influences critical molecular pathways involved in tumor progression, invasion, angiogenesis and metastasis in a wide range of cancer types. Hence, altering miRNA levels in cancer cells has promising potential as a therapeutic intervention, which is discussed in many other articles in this Special Issue. Some of the most significant hurdles in therapeutic miRNA usage are the stability and the delivery system. In this review, we cover a comprehensive update on the challenges and strategies for the development of therapeutic miRNA delivery systems that includes virus-based delivery, non-viral delivery (artificial lipid-based vesicles, polymer-based or chemical structures), and recently emerged extracellular vesicle (EV)-based delivery systems. View Full-Text
Keywords: microRNA delivery; cancer therapy; therapeutic RNA; extracellular vesicles microRNA delivery; cancer therapy; therapeutic RNA; extracellular vesicles
Show Figures

Figure 1

MDPI and ACS Style

Forterre, A.; Komuro, H.; Aminova, S.; Harada, M. A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers 2020, 12, 1852. https://doi.org/10.3390/cancers12071852

AMA Style

Forterre A, Komuro H, Aminova S, Harada M. A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers. 2020; 12(7):1852. https://doi.org/10.3390/cancers12071852

Chicago/Turabian Style

Forterre, Alexis, Hiroaki Komuro, Shakhlo Aminova, and Masako Harada. 2020. "A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies" Cancers 12, no. 7: 1852. https://doi.org/10.3390/cancers12071852

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop